Before 2007
In 1996, Cardinal Health acquired PCI of Philadelphia, Pennsylvania, a pharmaceutical contract packing service for commercial and clinical packaging.[2][3]
In 1998, Cardinal Health acquired R.P. Scherer Corporation of Troy, Michigan for $2.2 billion; it was founded by Robert Pauli Scherer to commercialize his innovation of softgel encapsulation using the rotary die production process.[4][5][6]
In 1999, Cardinal Health acquired Automatic Liquid Packaging of Woodstock, Illinois, thereby entering the sterile product market with blow fill seal technology.[7]
In January 2001, Cardinal Health acquired International Processing Corporation, a company that was renowned for its expertise in oral modified-release dosage form development and manufacturing, for $40 million.[8] In April 2002, Cardinal Health acquired Magellan Laboratories, a company that specialized in product development expertise.[9]
In October 2003, Cardinal Health acquired Gala Biotech of Madison, Wisconsin for $15.5 million.[10]
It also acquired Intercare Group of the UK for $530 million, broadening its global capabilities in Europe.[11]
2007–2019
In April 2007, the pharmaceutical technologies and services segment of Cardinal Health was acquired by affiliates of The Blackstone Group and re-branded as Catalent Pharma Solutions.[12][13]
In February 2012, Catalent acquired Aptuit, a clinical supply company. As part of the deal, Catalent gained three sites in the US, two in the UK, and one in Singapore.[14][15] Catalent also acquired all remaining shares for the R.P Scherer site in Eberbach, Germany.[6][16]
In March 2013, Catalent continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology, a China-based company, and Relthy Laboratories in Brazil.
2020–present
In January 2020, Catalent purchased a manufacturing facility located in Anagni, Italy, from Bristol-Myers Squibb, to manufacture and package biologic and oral solid dose products for multiple companies.[32]
In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million, to expand into cell therapy development.[33][34]
In 2020, Catalent partnered with multiple drugmakers, including Pfizer, Johnson & Johnson,[35] AstraZeneca,[36]
